Innocan Pharma Reports Strong Q1 Growth and Pipeline Progress
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HERZLIYA, Israel and CALGARY, Alberta, May 27, 2026 Innocan Pharma Corporation has reported strong first-quarter 2026 financial results, highlighting...
MORRISTOWN, N.J., May 21, 2026 Whitehawk Therapeutics has announced a major expansion of its antibody-drug conjugate (ADC) oncology pipeline...
GALWAY, Ireland, May 20, 2026 Medtronic plc has announced its intent to acquire SPR Therapeutics, Inc. in a deal...
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Encoded Therapeutics announced new preclinical findings at the 2026 American Society of...
SAN DIEGO, April 30, 2026 Contineum Therapeutics, Inc. announced positive topline results from its Phase 1b clinical trial of...
MONTEREY, California, USA, April 28, 2026 BRC Therapeutics has announced that the U.S. Food and Drug Administration has cleared...
